Medtronic and Tandem Diabetes Care Ink Patent Deal
June 18, 2020
and Tandem Diabetes Care have entered into a non-exclusive patent
cross-license agreement for certain technologies in the field of
diabetes. Cross-licensing each otherís patent portfolios enables both
companies to focus on helping people with diabetes through innovation of
future products and services, while avoiding the distraction of
potential legal disagreements.